[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201391076A1 - Комбинации - Google Patents

Комбинации

Info

Publication number
EA201391076A1
EA201391076A1 EA201391076A EA201391076A EA201391076A1 EA 201391076 A1 EA201391076 A1 EA 201391076A1 EA 201391076 A EA201391076 A EA 201391076A EA 201391076 A EA201391076 A EA 201391076A EA 201391076 A1 EA201391076 A1 EA 201391076A1
Authority
EA
Eurasian Patent Office
Prior art keywords
amino
pharmaceutically acceptable
acceptable salt
ovarian cancer
treating ovarian
Prior art date
Application number
EA201391076A
Other languages
English (en)
Inventor
Курт Р. Оджер
Джастин Боттсфорд-Миллер
Анил К. Суд
Original Assignee
Глэксосмитклайн Интеллекчуал Проперти Лимитед
Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глэксосмитклайн Интеллекчуал Проперти Лимитед, Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем filed Critical Глэксосмитклайн Интеллекчуал Проперти Лимитед
Publication of EA201391076A1 publication Critical patent/EA201391076A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к способу лечения рака яичников у женщины и к пригодным для такого лечения фармацевтическим комбинациям. В частности, способ относится к способу лечения рака яичников, который включает введение нуждающейся в этом пациентке 5-[[4-[(2,3-диметил-2H-индазол-6-ил)метиламино]-2-пиримидинил]амино]-2-метилбензолсульфонамида или его фармацевтически приемлемой соли и 2-[(5-хлор-2-[[3-метил-1-(1-метилэтил)-1H-пиразол-5-ил]амино]-4-пиридинил)амино]-N-метоксибензамида или его фармацевтически приемлемой соли, и необязательно 1,7β, 10β-тригидрокси-9-оксо-5β,20-эпокситакс-11-ен-2α,4,13α-триил-4-ацетат-2-бензоат-13-{(2R,3S)-3-[(трет-бутоксикарбонил)амино]-2-гидрокси-3-фенилпропаноата}.
EA201391076A 2011-01-26 2012-01-26 Комбинации EA201391076A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161436435P 2011-01-26 2011-01-26
PCT/US2012/022638 WO2012103276A1 (en) 2011-01-26 2012-01-26 Combinations

Publications (1)

Publication Number Publication Date
EA201391076A1 true EA201391076A1 (ru) 2014-07-30

Family

ID=46581159

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391076A EA201391076A1 (ru) 2011-01-26 2012-01-26 Комбинации

Country Status (13)

Country Link
US (2) US20130296356A1 (ru)
EP (1) EP2667871A4 (ru)
JP (1) JP2014503589A (ru)
KR (1) KR20140011322A (ru)
CN (1) CN103476413B (ru)
AU (1) AU2012209100A1 (ru)
BR (1) BR112013018565A2 (ru)
CA (1) CA2825790A1 (ru)
EA (1) EA201391076A1 (ru)
IL (1) IL227377A0 (ru)
MX (1) MX2013008654A (ru)
SG (1) SG191926A1 (ru)
WO (1) WO2012103276A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014009892A (es) * 2012-02-17 2015-02-12 Pharmacyclics Inc Combinaciones de inhibidor de histona desacetilasa y pazopanib y usos de las mismas.
RU2015117483A (ru) * 2012-10-12 2016-12-10 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Комбинации
WO2014066204A1 (en) * 2012-10-22 2014-05-01 Glaxosmithkline Llc Combination
EP2925728A4 (en) * 2012-11-27 2016-11-02 Glaxosmithkline Llc COMBINATION

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034860B2 (en) * 2006-07-21 2011-10-11 Eastman Specialties Holdings Corporation Organosol plastisol compositions
WO2008115369A2 (en) * 2007-03-16 2008-09-25 The Scripps Research Institute Inhibitors of focal adhesion kinase
BRPI0914927B8 (pt) * 2008-06-17 2021-05-25 Astrazeneca Ab composto, composição farmacêutica e uso de um composto
US20110301113A1 (en) * 2008-09-26 2011-12-08 Concert Pharmaceuticals Inc. Pyridineamine derivatives
JO3067B1 (ar) * 2008-10-27 2017-03-15 Glaxosmithkline Llc بيرميدينات بيرازولو امينو كمثبطات ل fak

Also Published As

Publication number Publication date
MX2013008654A (es) 2013-09-02
IL227377A0 (en) 2013-09-30
EP2667871A1 (en) 2013-12-04
CA2825790A1 (en) 2012-08-02
EP2667871A4 (en) 2014-07-09
AU2012209100A1 (en) 2013-08-01
KR20140011322A (ko) 2014-01-28
US20130296356A1 (en) 2013-11-07
US20160067248A1 (en) 2016-03-10
WO2012103276A1 (en) 2012-08-02
BR112013018565A2 (pt) 2016-09-27
CN103476413A (zh) 2013-12-25
CN103476413B (zh) 2016-03-16
JP2014503589A (ja) 2014-02-13
SG191926A1 (en) 2013-08-30

Similar Documents

Publication Publication Date Title
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
EA201790653A1 (ru) Способ лечения болезни альцгеймера и других расстройств
MX2016008362A (es) Combinaciones farmaceuticas.
UA94734C2 (ru) ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ
JO3776B1 (ar) التركيبات الصيدلانية لمثبط CDK4 / 6 ومثبط B-Raf
EA201490014A1 (ru) Модифицированное высвобождение 4-метил-3-[[4-(3-пиридинил)-2-пиримидинил]амино]-n-[5-(4-метил-1h-имидазол-1-ил)-3-(трифторметил)фенил]бензамида, солюбилизированного с использованием органических кислот
NZ703940A (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
EA201490254A1 (ru) Комбинированное лечение гепатита с
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
EA201270071A1 (ru) Способ лечения пациента, нуждающегося в аспириновой терапии
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
EA201391027A1 (ru) Комбинация
MX2014002471A (es) Combinaciones sinergicas de los inhibidores de p13k y mek.
WO2008049984A3 (fr) Utilisation de la citrulline pour le traitement des etats de denutrition
EA201291167A1 (ru) Замещенные гетероциклилбензилпиразолы и их применение
WO2013071056A3 (en) Combination drug therapy for the treatment of solid tumors
EA201590193A1 (ru) Препараты лаквинимода без подщелачивающего агента
EA201391076A1 (ru) Комбинации
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
EA201270526A1 (ru) Комбинация
UA115250C2 (uk) Фармацевтичні комбінації
EA201270527A1 (ru) Комбинация
EA201391327A1 (ru) Терапевтическое лечение
MX2016010482A (es) Combinaciones farmaceuticas que comprenden un inhibidor de pi3k para el tratamiento de cancer.